Prognostic impact of cytokines and chemokines in bronchoalveolar lavage fluid on acute exacerbation of fibrosing interstitial lung disease.

Autor: Furuta K; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Fujimoto D; Internal Medicine III, Wakayama Medical University, Wakayama, Japan. Electronic address: daichi@wakayama-med.ac.jp., Matsunashi A; Department of Respiratory Medicine, Kobe City Medical Center General Hospital Kobe, Japan., Shibaki R; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Taniya S; Revorf. Co., Ltd., Tokyo, Japan., Tanaka M; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Shimada Y; Department of Respiratory Medicine, Kobe City Medical Center General Hospital Kobe, Japan., Nagata K; Department of Respiratory Medicine, Kobe City Medical Center General Hospital Kobe, Japan., Tomii K; Department of Respiratory Medicine, Kobe City Medical Center General Hospital Kobe, Japan., Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2024 Sep; Vol. 231, pp. 107721. Date of Electronic Publication: 2024 Jul 05.
DOI: 10.1016/j.rmed.2024.107721
Abstrakt: Background and Objective: Acute exacerbation of fibrosing interstitial lung disease (AE-FILD) is a serious condition with a high mortality rate. We aimed to comprehensively analyze cytokines in bronchoalveolar lavage fluid and their association with the clinical course of AE-FILD.
Methods: We retrospectively enrolled 60 patients with AE-FILD who underwent bronchoalveolar lavage. We comprehensively measured 44 cytokines and chemokines in the obtained bronchoalveolar lavage fluid using a Luminex analyzer. Patients were grouped into those who died within 90 days (non-survival group) and survived beyond 90 days (survival group) to investigate the association of the levels of cytokines and chemokines with mortality.
Results: The levels of matrix metalloproteinase 1 (p = 0.003), granulocyte-macrophage colony-stimulating factor (p = 0.040), interleukin 6 (p = 0.047), interleukin 8 (p = 0.050), monocyte chemoattractant protein-1 (p = 0.043), and eotaxin (p = 0.044) were significantly higher in the non-survival group than in the survival group. In the receiver operating characteristic analysis, their areas under the curve were 0.80, 0.68, 0.71, 0.70, 0.70, and 0.72, respectively. Using machine learning with these six cytokines and chemokines, the predictive accuracy for the survival group was 0.94.
Conclusions: Our study demonstrated that several cytokines and chemokines in bronchoalveolar lavage fluid could be prognostic predictors in patients with AE-FILD.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: K.F. received honoraria from Boehringer Ingelheim Japan, AstraZeneca KK, and Chugai Pharmaceutical. D.F. received grants from AstraZeneca KK and Boehringer Ingelheim Japan. D.F. received honoraria from AstraZeneca KK, Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD KK, Boehringer Ingelheim Japan, Eli Lilly Japan KK, Novartis Pharma KK, Kyowa Kirin, and Janssen Pharmaceutical KK. D.F. is on the advisory boards of AstraZeneca KK and Chugai Pharmaceutical. S.T. received analysis support from Revorf Co., Ltd. K.N. received honoraria from Teijin Pharma, Teijin Healthcare, Philips Japan, and Fisher & Paykel Healthcare. K.T. received payment for presentation from Boehringer Ingelheim Japan and Shionogi & Co. N.Y. received grants from Boehringer Ingelheim Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Shionogi & Co., Eli Lilly Japan KK, Daiichi Sankyo, Tumura & Co., Nippon Kayaku Co., Asahikasei-pharma Co., Janssen Pharmaceutical KK, Sanofi KK, Amgen KK, Novartis Pharma KK, Astellas Pharma, MSD KK, Eisai Co., Bristol-Myers Squibb, AbbVie, and TOSOH Co. N.Y. received honoraria from Boehringer Ingelheim Japan, MSD KK, AstraZeneca KK, Amgen KK, Ono Pharmaceutical, Otsuka Pharmaceutical, Guardant Health Japan, Tumura & Co., Kyowa Kirin Co., Kyorin Pharmaceutical Co., GlaxoSmithKline Consumer Healthcare Japan KK, Sanofi KK, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan KK, Nippon Kayaku Co., Novartis Pharma KK, Pfizer, Bristol-Myers Squibb, Miyarisan Pharmaceutical, Merck & Co., and Janssen Pharmaceutical KK. N.Y. is on the advisory boards of AstraZeneca KK, Eli Lilly Japan KK, and Takeda Pharmaceutical. Other co-authors have no conflicts of interest to declare. This study was funded by Boehringer Ingelheim Japan.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: